a Clinical Research of BCMA-Targeted Prime CAR-T Cell Therapy in Relapsed/Refractory Multiple Myeloma and Plasma Cell Disease

NCT04776330 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

RECRUITING

Status

80

Enrollment

INDUSTRY

Sponsor class

Conditions

Multiple Myeloma
Neoplasm, Plasma Cell
Multiple Myeloma in Relapse

Interventions

BIOLOGICAL: BCMA targeted prime CAR-T cells

Sponsor

Chongqing Precision Biotech Co., Ltd